| Name | N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide |
|---|---|
| Synonyms | Saredutant |
| Description | Saredutant is a selective NK2 receptor antagonist. |
|---|---|
| Related Catalog | |
| Target |
NK2 |
| In Vivo | Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression. Saredutant has dose-dependent effects on swim test immobility, with the low dose of 1 mg/kg having no effect and the doses of 3 and 10 mg/kg significantly reducing immobility[1]. |
| Animal Admin | Rats[1] In the first experiment the dose-related effects of Saredutant are investigated. The Flinders Sensitive Line (FSL) rats (n=8) are treated with one of the following: vehicle (carboxymethylcellulose-CMC) or 1, 3, or 10 mg/kg Saredutant, or 5 mg/kg Desipramine as a positive control. Saredutant is injected at 1 mL/kg. The Flinders Resistant Line (FRL) rats are given CMC or 3 mg/kg Saredutant. All injections are i.p. and are given for 14 consecutive days. Approximately 22 h after the last injections the rats are placed in the social interaction chamber with similarly treated rats for a 5-min recording. Then about 2 h later the rats are individually tested in the forced swim test for a single 5-min session[1]. |
| References |
| Density | 1.26g/cm3 |
|---|---|
| Boiling Point | 734.7ºC at 760mmHg |
| Molecular Formula | C31H35Cl2N3O2 |
| Molecular Weight | 552.53400 |
| Flash Point | 398.1ºC |
| Exact Mass | 551.21100 |
| PSA | 52.65000 |
| LogP | 6.69550 |
| Vapour Pressure | 1.91E-21mmHg at 25°C |
| Index of Refraction | 1.628 |